SCG Therapy Opens Cell Therapy Manufacturing Facility in Singapore
The new facility is set to utilize and extend SCG's capabilities in advanced cell therapy manufacturing and off-the-shelf human-induced Pluripotent Stem Cell (iPSC) technology.
SCG Therapy opened its new cell therapy manufacturing facility and research and development center in Singapore, the company announced on July 20, 2023, to pioneer Singapore’s Manufacturing 2030 Vision, according to a company press release.
The new facility is set to utilize and extend SCG's capabilities in advanced cell therapy manufacturing and off-the-shelf human-induced Pluripotent Stem Cell (iPSC) technology. Further, the facility will supply cell therapy products to partner hospitals in Asia Pacific, North America, and Europe, according to the release.
"Cell therapy has demonstrated the potential to revolutionize treatment for cancers and other life-threatening diseases. However, the high manufacturing costs and supply limitation are limiting patient access to the treatment,” said Christy Ma, chief strategy officer of SCG Cell Therapy, in a press release.
Low Yen Ling, minister of state at the Ministry of Trade and Industry, described that Singapore’s Manufacturing 2030 vision aims to position Singapore as a global business, innovation, and talent hub for advanced manufacturing. “The biotechnology sector is an important flank of our strategy. Today, we have a thriving ecosystem comprising both local and global companies pursuing their ambitions in biotechnology from Singapore,” Ling said in a press release. “SCG Cell Therapy is one of our promising local startups, developed its first cell therapy product, SCG101, with the support of agencies like the Health Sciences Authority (HSA) and the Agency for Science, Technology and Research (A*STAR). Headquartered in Singapore, and with teams in China and Germany, SCG Cell Therapy offers the entire drug development cycle—from research and development (R&D), GMP manufacturing, and clinical development to commercialization. The cGMP [current good manufacturing practice] facility will enable SCG Cell Therapy to further scale its operations. Its development augurs well for the growth of our biotech sector.”
Source: SCG
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
